
Our stories
/
Science
Immunotherapy
Scientific American series: Emerging trends in immuno-oncology
Bristol Myers Squibb is underwriting a series in partnership with Scientific American to highlight emerging trends in Immuno-Oncology (I-O) and their impact on the future of cancer care.
November 26, 2018
As part of our focus to better understand cancer biology and the intersection with the immune system, we’ve partnered with
Scientific American
to underwrite an editorial series highlighting emerging trends in I-O, with a particular focus on biomarkers. The series, which kicked off during the Society for Immunotherapy of Cancer 32 nd
Annual Meeting, will feature perspectives from Bristol Myers Squibb researchers on the latest challenges and discoveries in I-O.
The #1 Challenge in Cancer Research
Using the immune system to fight cancer has been a groundbreaking scientific advancement, but researchers are still working to bring this science to more patients.
Read More >
Uncovering Cancer's Genetic Fingerprint
Researchers are decoding the latest information on an emerging biomarker known as tumor mutation burden (TMB).
Read More >
Exploring the Tumor Microenvironment
Researchers are shining a light on the tumor microenvironment to accelerate the next generation of cancer treatments.
Read More >
related articles
Revelations in oncology: Reflecting on the past and charting the future in cancer research >
One woman's account of living with ulcerative colitis >
Doing R&D "differently" to transform treatment for serious diseases >

March 17, 2021
© 2024
Bristol-Myers Squibb Company